

# N-acetylcysteine and coronavirus disease 2019: May it work as a beneficial preventive and adjuvant therapy? A comprehensive review study

Najmolsadat Atefi<sup>1</sup>, Elham Behrangi<sup>1</sup>, Samaneh Mozafarpour<sup>2</sup>, Farnoosh Seirafianpour<sup>3</sup>, Shadi Peighambari<sup>4</sup>, Azadeh Goodarzi<sup>1</sup>

<sup>1</sup>Department of Dermatology, Rasoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran, <sup>2</sup>Department of Dermatology, Skin Disease and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran, <sup>3</sup>Department of General Medicine, Student Research Committee, School of Medicine, Iran University of Medical Sciences, Tehran, <sup>4</sup>Department of Internal Medicine, San Joaquin General Hospital, CA, USA

**Background:** Coronaviruses are major pathogens of respiratory system causing different disorders, including the common cold, Middle East respiratory syndrome, and severe acute respiratory syndrome. Today's global pandemic coronavirus disease 2019 (COVID-19) has high mortality rate, with an approximate of 20% in some studies, and is 30–60 times more fatal than the common annual influenza. However, there is still no gold standard treatment for it. N-acetylcysteine (NAC) is a well-known multi-potential drug with hypothetically probable acceptable effect on COVID-related consequences, which we completely focused in this comprehensive review. **Materials and Methods:** PubMed, Scopus, Science Direct, and Google Scholar have been searched. Study eligibility criteria: efficacy of NAC in various subclasses of pathogenic events which may occur during COVID-19 infection. Efficacy of NAC for managing inflammatory or any symptoms similar to symptoms of COVID-19 was reviewed and symptom improvements were assessed. **Results:** Randomized clinical trials introduced NAC as an antioxidant glutathione analog and detoxifying agent promoted for different medical conditions and pulmonary disorders to alleviate influenza and reduce mortality by 50% in influenza-infected animals. The beneficial effects of NAC on viral disorders, including Epstein–Barr virus, HIV and hepatitis, and well-known vital organ damages were also exist and reported. **Conclusion:** We classified the probable effects of NAC as oxidative-regulatory and apoptotic-regulatory roles, antiviral activities, anti-inflammatory roles, preventive and therapeutic roles in lung disorders and better oxygenation functions, supportive roles in intensive care unit admitted patients and in sepsis, positive role in other comorbidities and nonpulmonary end-organ damages or failures and even in primary COVID-associated cutaneous manifestations. Based on different beneficial effects of NAC, it could be administered as a potential adjuvant therapy for COVID-19 considering patient status, contraindications, and possible drug-related adverse events.

**Keywords:** Acute respiratory distress syndrome, adjuvant therapy, anti-inflammatory, anti-oxidant, anti-viral, comprehensive review, coronavirus, COVID-19, N-acetylcysteine, organ failure, prevention, pulmonary, respiratory, treatment

**How to cite this article:** Atefi N, Behrangi E, Mozafarpour S, Seirafianpour F, Peighambari S, Goodarzi A. N-acetylcysteine and coronavirus disease 2019: May it work as a beneficial preventive and adjuvant therapy? A comprehensive review study. *J Res Med Sci* 2020;25:109.

## INTRODUCTION

According to the WHO, severe acute respiratory syndrome (SARS)-coronavirus, Hemagglutinin Type 1 and Neuraminidase Type 1 (H1N1) Influenza, and Middle East respiratory syndrome (MERS)-Coronavirus caused epidemics in the past 20 years. Coronaviruses are major pathogens of respiratory diseases causing different

diseases, including the common cold, MERS, and SARS. The current pandemic of COVID-19 began from Wuhan, China.<sup>[1-8]</sup> The clinical spectrum of COVID-19 involves asymptomatic and pauci-symptomatic conditions, including dry coughs, malaise, fever, dyspnea, respiratory failure requiring mechanical ventilation in intensive care units (ICUs), multi-organ and systemic manifestations as sepsis, septic shocks, and multiple organ dysfunction syndrome (MODS).<sup>[1-4]</sup> Approximately

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

**For reprints contact:** WKHLRPMedknow\_reprints@wolterskluwer.com

Access this article online	
Quick Response Code: 	Website: <a href="http://www.jmsjournal.net">www.jmsjournal.net</a>
	DOI: 10.4103/jrms.JRMS_777_20

**Address for correspondence:** Dr. Azadeh Goodarzi, Department of Dermatology, Rasoul Akram Hospital, Nyayesh Street, Sattarkhan Avenue, Postal Code: 1445613131, Tehran, Iran. E-mail: [goodarzi.a@iums.ac.ir](mailto:goodarzi.a@iums.ac.ir) and [azadeh\\_goodarzi1984@yahoo.com](mailto:azadeh_goodarzi1984@yahoo.com)

**Submitted:** 07-Jul-2020; **Revised:** 11-Aug-2020; **Accepted:** 25-Sep-2020; **Published:** 26-Nov-2020

one-third of the patients require ICU hospitalization, and literature suggests a mortality of 15%.<sup>[5]</sup> Mortality was reported as approximately 49.0% in critical patients with comorbid cardiovascular disease, hypertension, diabetes, chronic respiratory diseases, or cancer.<sup>[5]</sup> The mild type of COVID-19 was observed in 81% of the cases presenting with nonpneumonia and mild pneumonia, the severe type in 14% with dyspnea and a respiratory frequency of at least 30/min, a maximum blood oxygen saturation (SpO<sub>2</sub>) of 93%, PaO<sub>2</sub>/FiO<sub>2</sub> of below 300 and/or pulmonary infiltrates of over 50% in 24–48 h and the critical type in 5% with respiratory failure, septic shocks or multiple organ failure (MOF) and/or MODS.<sup>[1-8]</sup> Despite the desirable clinical course of the disease in the majority of the patients, a sudden exacerbation of clinical conditions with rapidly worsening respiratory failure and MODS/MOF has been reported. The WHO recommends PCR on paired upper and lower respiratory tract samples for diagnosing COVID-19.<sup>[1-3]</sup>

No specific antiviral treatments or vaccines have been yet recommended or approved for COVID-19. The National Institute for Allergy and Infectious Diseases has announced the first phase of a trial on a novel coronavirus immunization in Washington. The treatment is symptomatic, and oxygen therapy is the main intervention in patients with severe infections. Mechanical ventilation may be required in cases of respiratory failure refractory to oxygen therapy, whereas hemodynamic support is essential for managing septic shocks. Intubation, protective mechanical ventilation, high-flow nasal oxygen therapy, and NIV are used in respiratory failure. Respiratory and organ function support is mandatory in complex clinical pictures of MOD. Hemoperfusion and extracorporeal membrane oxygenation should be considered in the patients with refractory hypoxemia under lung-protective ventilation or with poor outcomes of prone ventilation. Although no antiviral treatments have been approved, alpha-interferon and lopinavir/ritonavir have been proposed. Although both chloroquine and hydroxychloroquine inhibit SARS-CoV-2 *in vitro*, the seemingly more potent antiviral activity of the latter is beneficial in COVID-19. Tocilizumab, an IL-6 inhibitor, has been proposed in patients with severe COVID-19. Remdesivir, an RNA polymerase inhibitor with *in vitro* activities against multiple RNA viruses such as Ebola, can contribute to the prophylaxis and treatment of coronavirus infections. Given the lack of evidence, the application of systemic corticosteroids to treating viral pneumonia and acute respiratory distress syndrome (ARDS) is controversial; methylprednisolone was, however, reported as useful. Moreover, antibiotics should not be unselectively or inappropriately administered. As an optimal antiviral intervention, prolonged viral shedding can be applied for a

median duration of 20 days in survivors and permanently in fatal cases to isolate infected patients. Accurately evaluating potential medications in terms of effectiveness and safety is crucial for determining the mechanisms through which they target the pathogenic course of COVID-19.<sup>[1-3,9,10]</sup> Human pathogenic coronaviruses bind to target cells through angiotensin-converting enzyme 2 (ACE2), which is expressed by epithelial cells of the lung, intestine, kidney, and blood vessels. This expression is substantially increased in patients with Type 1 or 2 diabetes treated with ACE inhibitors and angiotensin II type 1 receptor blockers (ARBs). Treating hypertension with ACE inhibitors and ARBs also causes the upregulation of ACE2. Thiazolidinediones as a diabetes treatment and ibuprofen can also increase ACE2. Diabetes and its medications and ACE inhibitors and ARBs used in hypertension therefore increase the ACE2 expression and the risk of COVID-19. ACE2-stimulating drugs used to treat diabetes and hypertension can also increase the risk of developing severe and fatal COVID-19. Patients with cardiac diseases, hypertension, and diabetes treated with ACE2-increasing drugs, who are at higher risks for severe COVID-19, should be therefore monitored for ACE2-modulating medications, including ACE inhibitors and ARBs. Furthermore, antihypertensive calcium channel blockers are recommended in these patients.<sup>[11]</sup>

As an acetylated variant and precursor of L-cysteine, a scavenger of free radicals, especially oxygen radicals, a strong antioxidant in certain conditions, a nutritional supplement and the cause of glutathione biosynthesis and elevation, N-acetylcysteine (NAC) is commonly used as a specific antidote for acetaminophen overdose and medical conditions related to glutathione synthetase deficiency. NAC exerts its therapeutic effects in hepatotoxic acetaminophen overdose through several mechanisms, and functions as a precursor for the substrate (L-cysteine) in the synthesis of hepatic glutathione depleted through acetaminophen conjugation. N-acetylcysteine alleviates the clinical symptoms of cystic fibrosis through the cysteine-mediated disruption to disulfide cross-bridges in the glycoprotein matrix in mucus. Glucuronidation and sulfation (>90%) at therapeutic doses mainly contribute to acetaminophen metabolism. Below 5% of the drug oxidized by CYP450 isoforms, mainly CYP2E1, produces a toxic metabolite, namely N-acetyl-p-benzoquinone imine (NAPQI), as a precursor of cell injury. Glutathione can normally detoxify these minuscule quantities of NAPQI in the liver and prevent tissue damage. In acetaminophen overdose, glucuronidation and sulfation pathways are saturated, and the more significant CYP450 pathway produces more toxic metabolites, which depletes glutathione reserves and causes their accumulation and tissue injury through binding to

cellular macromolecules.<sup>[12-17]</sup> The anti-oxidative activity of NAC is attributed to fast reactions with free radicals and restitution of glutathione; nevertheless, NAC by itself should not be considered a strong antioxidant, as its strength depends on the targeted replenishment of glutathione in deficient cells, which improves its efficacy in certain circumstances, including inflammatory processes and oxidative stress.<sup>[12-17]</sup>

We know that, there are not any specific virus-targeted gold standard therapies for COVID-19 infection. Most of the proposed drugs are immunomodulators for regulating virus-host associated cytokine and inflammation storms. Many of the immunomodulators have immunosuppressant characteristics which may not work properly in a setting of a viral disorder.<sup>[1-3]</sup>

NAC is an immunomodulators without immunosuppressant characteristics.<sup>[12,13]</sup>

N-acetylcysteine (NAC) is a multi-potential drug with a wide variety of use in different medical conditions especially with its anti-inflammatory, anti-oxidative, and respiratory supportive effects like positive effect on respiratory outcomes such as ARDS and other end-organ failures.<sup>[12,13]</sup>

Hence, the aim of this study was classification of probable effects of NAC in many categories of COVID-19-associated consequences.

## MATERIALS AND METHODS

Although this study covered a wide topic therefore hard to be written as a systematic review article, we managed to write it to some extent in a systematized and well-classified search and manner.

### Eligibility criteria

Inclusion criteria comprised all studies about COVID-19 symptoms and pathogenesis and all studies about N-acetylcysteine mechanisms and applications and efficacy of NAC in various subclasses of pathogenic events which may occurs during COVID-19 infection.

For this review, humans or animal studies which focused on NAC for managing inflammatory or any symptoms similar to symptoms of COVID-19, were reviewed and symptoms improvement were assessed. The exclusion criteria consisted of all publications not meeting the above and non-English literature.

### Information sources

Databases PubMed (<http://ncbi.nlm.nih.gov/pubmed>), Scopus (<http://www.scopus.com>), Science Direct ([https://](https://www.sciencedirect.com)

[www.sciencedirect.com](https://www.sciencedirect.com)), and Google Scholar (<https://scholar.google.com/>) have been searched for the evidence.

### Search strategy

The search was performed by keywords COVID-19, corona viruses, COVID-19 symptoms, novel coronavirus, coronavirus pneumonia, coronavirus disease, inflammation symptoms and their synonyms. N-acetylcysteine and their synonyms, and N-acetylcysteine with each subclass searched separately. Search was not limited to the entries to any condition. The search started and completed on April 22, 2020. The period of search was any articles published until April 22, 2020.

### Study selection

Endnote® X8 (Clarivate Analytics, Philadelphia, USA) was used for study screening and data extraction. 900 articles assigned to the inclusion and exclusion groups. In the first step, the titles and abstracts of articles were read. Moreover, if accepted has evaluated to second step; 400 article went to the full-text screening; the authors read the full-text and executed the final inclusion articles based on the highest level of evidence.

## RESULT

### Study selection

From 400 articles 111 article met inclusion criteria at final and their data were used for this review.

### Results of individual studies

COVID-19 is categorized by respiratory features as follows:<sup>[1-3]</sup> nonsevere/critical cases divided into uncomplicated mild cases presenting with symptoms of upper respiratory tract viral infections, including mild fever, sore throat, dry coughs, malaise, nasal congestion, headache, and muscle pain.

- Moderate pneumonia cases presenting with respiratory symptoms, including coughs and shortness of breath or tachypnea in children without symptoms of severe pneumonia
- Severe pneumonia cases whose moderate fever, if any, is associated with severe dyspnea, respiratory distress, tachypnea (over 30 breaths/min) and hypoxia ( $SpO_2 < 90\%$  on room air)
- ARDS cases whose diagnosis requires clinical measures and ventilation. Characterized by an emerging serious respiratory failure or the worsening of an already-diagnosed respiratory dysfunction, ARDS is classified by the degree of hypoxia ( $PaO_2/FiO_2$ ) as severe, i.e.,  $PaO_2/FiO_2 \leq 100$  mmHg, moderate, i.e.,  $100$  mmHg  $< PaO_2/FiO_2 \leq 200$  mmHg, and mild, i.e.,  $200$  mmHg  $< PaO_2/FiO_2 \leq 300$  mmHg in the nonventilated

patients or in those managed through noninvasive ventilation (NIV) using positive end-expiratory pressure or continuous positive airway pressure (CPAP)  $\geq 5$  cmH<sub>2</sub>O.

In the cases of unavailable PaO<sub>2</sub>, SpO<sub>2</sub>/FiO<sub>2</sub>  $\leq 315$  can suggest ARDS. Despite the need for excluding nonpulmonary origins such as cardiac failure and fluid overload, the clinical scenario and ventilator data can suggest pulmonary edema in some cases. Sepsis can occur as a life-threatening organ dysfunction due to dysregulated host responses to COVID-19 emerging as severe dyspnea and hypoxemia, renal impairment with reduced urine output, tachycardia, altered mental status and functional alterations of organs expressed as laboratory data of hyperbilirubinemia, acidosis, high lactate, coagulopathy, thrombocytopenia, and the associated hypotension in septic shocks.<sup>[1-3,18-22]</sup>

Accidental findings obtained from histopathological evaluations of the lung in COVID-19 patients suggested edema, important proteinaceous exudates as large protein globules, vascular congestion comorbid with inflammatory clusters of fibrinoid materials, multinucleated giant cells and pneumocyte hyperplasia. Lung histopathological evaluations in autopsy also suggested bilateral diffuse alveolar damage with cellular fibromyxoid exudates. Moreover, desquamated pneumocytes and hyaline membrane formation, suggesting interstitial mononuclear inflammatory infiltrates, were also reported in ARDS dominated by lymphocytes. Cytopathic effects with no obvious intranuclear or intracytoplasmic viral inclusions could also be identified as multinucleated syncytial cells with atypically enlarged pneumocytes characterized by large nuclei, amphophilic granular cytoplasm and prominent nucleoli in intra-alveolar spaces.<sup>[1,23]</sup>

COVID-19 can cause pneumonia and damage other organs and systems, including the heart, liver, kidney, blood, and the immune system. MOF, shocks, ARDS, heart failure, arrhythmias, and renal failure can eventually cause death. Basic treatments, including antivirals, antibiotics, oxygen therapy, and glucocorticoids, were administered for the pneumonia observed in 22% of the patients classified as type A. Individual evaluations should be performed and specific treatment plans, including antihypertensives, hypoglycemic, and continuous renal replacement therapy, be developed to monitor serious comorbidities and manage different degrees of pneumonia in 55% of the patients classified as Type B. The unsatisfactory effects of early treatments on Type A or the aggravation of original comorbidities in Type B, both causing MOF, can turn into the critical disease classified as Type C (23%).<sup>[24]</sup>

Potential risk factors, including old age, high sequential organ failure assessment scores, and D-dimer over 1  $\mu$ g/mL,

can assist clinicians with the early-stage identification of patients with poor prognoses. Age, comorbidities, lymphocytopenia, elevated alanine aminotransferase, D-dimer, creatine kinase, high-sensitivity cardiac troponin I, prothrombin time, and disease severity were found associated with ICU admission.<sup>[10]</sup>

The critically ill patients with SARS-CoV-2 pneumonia are quite likely to die within 1–2 weeks of ICU admission. Patients aged over 65 with comorbidities and ARDS are also at higher risk of death.<sup>[25]</sup>

The ARDS risk and the associated mortality increase with reductions in immunologic responses caused by aging. High fever can be associated with both the development and improved outcomes of ARDS.<sup>[9]</sup>

### Mechanisms of N-acetylcysteine

N-acetylcysteine replenishes glutathione reserves by providing cysteine as an essential precursor of glutathione production, binds to toxic metabolites, scavenges free radicals, increases mitochondrial ATP production and oxygen delivery to tissues, and alters the microvascular tone to increase the blood flow and oxygen delivery to the liver and other vital organs. NAC is therefore a vital agent with oxidative-regulatory and apoptosis-regulatory effects.<sup>[12-17]</sup>

Patients with malnutrition, alcoholism, or cirrhosis and those using drugs that metabolized through CYP2E1 such as isoniazid are vulnerable to decreased glutathione reserves.<sup>[12]</sup>

NAC available at a 20% concentration in 30-mL vials and oral NAC available at 10% and 20% concentrations in 10-mL vials require dilution before IV administration. Six hundred milligram of IV NAC can be administered every 8 h in surgical patients and ICU patients with toxic epidermal necrolysis.<sup>[26,27]</sup>

Major complications of oral NAC include nausea, diarrhea, flatus, gastroesophageal reflux, and vomiting, which occurs in one-third of the patients. Oral NAC can also induce gastrointestinal bleeding in patients with gastrointestinal ulcers or varices.<sup>[20]</sup> IV NAC can cause anaphylactoid reactions in approximately 18% of patients, including 6% with mild reactions, 10% with moderate, and about 1% with severe reactions, including bronchospasm and hypotension. More commonly observed anaphylactoid reactions at low hepatotoxic acetaminophen levels can be explained by decreases in histamine release from mast cells and mononuclear cells by the ingested acetaminophen. More commonly observed bronchospasm in patients with reactive airway diseases, including asthma, require



bronchodilating agents. NAC should be immediately stopped and anti-histamines and IV fluid be administered rather than vasopressors for hypotension in anaphylactoid reactions. N-acetylcysteine therapy can be re-administered more slowly after the reaction resolution or used as an alternative oral medication in the case of persistent reactions. IV NAC can cause false-positive urine ketones and false increases in international normalized ratios, which normalize once infusion stops. The initial dose of IV NAC should be monitored in assessing anaphylactoid reactions potentially requiring prompt interventions. IV NAC is not recommended in patients with heart failure or cardiomyopathy, who are at risk for hypervolemia.<sup>[12]</sup> In overall, NAC is safe without any common or serious side effect or interaction, but in hepatic encephalopathy, asthma, fluid overload, and gastric hemorrhage, should not be use also the charcoal, ifosfamide and insulin inhalation (rapid acting, may adversely interact with NAC.<sup>[12]</sup>

Nebulized N-acetylcysteine plays mucolytic, anti-inflammatory, and antioxidant roles in respiratory diseases, including chronic obstructive bronchopulmonary disease (COPD) and cystic fibrosis. The administration routes of NAC include topical, oral, and IV in different medical indications and research on its therapeutic efficacy and ideal doses and most effective mode of delivery of these indications is ongoing.<sup>[26-40]</sup>

The applications of NAC include:<sup>[12-17,26-40]</sup>

- Acetaminophen (paracetamol) overdose
- Cystic fibrosis
- Mucolytic agent
- Preventing and treating pulmonary diseases, including ARDS, bronchitis, COPD, pneumonia, and idiopathic pulmonary fibrosis (IPF)
- Antineoplastic agent and cancer chemoprevention
- Psychiatric disorders, including bipolar disorder, schizophrenia, and depression
- Gastrointestinal disorders, including H. Pylori infections, and hepatorenal syndrome
- Infertility, including clomiphene-resistant polycystic ovary syndrome
- Necrotizing enterocolitis
- ICU patients with sepsis, cardiac injuries, MOF, and lung injuries
- Hematological diseases, including sickle cell disease
- Neurologically improving comatose patients with carbon monoxide poisoning
- Preventing contrast-induced nephropathy and thrombosis, i.e., kidney damage during imaging or after heavy surgeries, including coronary artery bypass
- Alleviating preexisting influenza
- Prophylaxis of gentamicin-induced hearing loss in patients undergoing hemodialysis

- Early stages of toxicity induced by nonacetaminophen drugs, alcohol, and pesticides
- Inflammatory and critical systemic disorders.

Preventing and treating dermatologic conditions, including toxic epidermal necrolysis, drug hypersensitivity syndrome, trichotillomania, excoriation disorder, onychotillomania, ichthyosis, contact dermatitis, atopic dermatitis, melasma, pseudoporphyria, connective tissue disorders, wounds, and alopecia as well as protecting against radiation-induced damage including radiation dermatitis, photoaging and photocarcinogenesis

The global demand for NAC as a plant antioxidant in onion is growing, especially in nutritional supplements and cosmetics. Randomized clinical trials (RCTs) suggest controversial and inconclusive evidence for this seemingly safe substance as in the case of other antioxidants. A systematic review and meta-analysis reported increasing side effects with the dose of NAC. Decisions should be therefore made considering the advantages and potential disadvantages.<sup>[41,42]</sup>

In addition to exerting anti-inflammatory and antioxidant effects, NAC alters neurotransmitter levels, inhibits the proliferation of fibroblasts and keratinocytes and causes vasodilatation. As systemic and topical forms, NAC is used in dermatologic applications.<sup>[26-28,35-41]</sup> Systematic reviews and meta-analyses in RCTs confirmed the safety, tolerability profile, and effectiveness of NAC in wound healing, photoprotection, pseudoporphyria, xeroderma pigmentosum, onychophagia, systemic sclerosis, Type-I lamellar ichthyosis, toxic epidermal necrolysis, eczema, trichotillomania, acne vulgaris, and bullous morphea.<sup>[43]</sup>

## DISCUSSION

### Summary of evidence

In the USA, influenza annually causes approximately 30,000 deaths and infection of 30 million people. The initially found mortality of the currently spread RNA coronavirus in China and all over the world is globally 1%–2% and 2.92% in the USA, which is much higher than that of the common flu, i.e., 0.05%–0.1%, compared to a case fatality of 2.3% in confirmed cases of COVID-19. The real mortality founded to be higher in further investigations of the pandemic. COVID-19 is 30–60 times more fatal than the annual flu,<sup>[1-8]</sup> as recent evidence suggests an approximate mortality of 20%.<sup>[5]</sup>

Both influenza and coronavirus cause inflammatory storms in the lungs, which cause organ failure, ARDS and death. Certain medications can reduce lung inflammations caused by RNA viruses and boost the associated Type I interferon

responses as the body's primary mechanism of producing antiviral antibodies to fight viral infections.<sup>[1,18-22]</sup>

The approved treatments for influenza are generally costly, ineffective, and complicated. Flu vaccines are effective in around half of the cases. Safer and more effective alternatives are therefore required for treating influenza. The management complication of COVID-19 caused by failing to yet propose specific targeted therapies requires serious assessments of potential treatments.<sup>[1-3]</sup>

RCTs suggest NAC with multiple potential medical applications reduces the influenza duration by 2–4 days and its severity. Nutraceuticals, including spirulina, glucosamine,  $\beta$ -glucans, and N-acetylcysteine, were found to reduce mortality by 50% and the infection severity in influenza-infected animals. The beneficial effects of NAC on other viral disorders, including HIV, Epstein–Barr virus and hepatitis, are highlighted in literature.<sup>[12,13,29-33,44-52]</sup>

NAC is a glutathione analog antioxidant promoted for treating a wide range of diseases such as pulmonary disorders, including IPF, ARDS, bronchitis, COPD, and pneumonia, which significantly increase mortality in COVID-19 patients. The potential benefits and effectiveness of NAC in coronaviruses are not addressed in literature.

The preventive and therapeutic effects of NAC on COVID-19 and its consequences include:

#### **Oxidative-regulatory and apoptotic-regulatory roles**

The anti-oxidative activity of NAC is attributed to fast reactions with free radicals and restitution of glutathione; nevertheless, NAC by itself should not be considered a strong antioxidant, as its strength depends on the targeted replenishment of glutathione in deficient cells, which improves its efficacy in certain circumstances, including inflammatory processes and oxidative stress.<sup>[12,13]</sup>

NAC regulates the activity of Group I metabotropic glutamate receptors (mGlu) in neuroprotection and neurotoxicity, reduces oxidative stress and increases cell survival. NAC can target the group I mGlu activation in treating Parkinson's disease. Significantly-reduced local induction of bax and caspase 3 and significantly increased the reduced local production of bcl-2 by N-acetylcysteine suggest its effectiveness in protecting the lungs against lipopolysaccharides.

NAC induces apoptosis via mitochondriadependent pathways rather than endoplasmic reticulum stress in H9c2 cells, and exogenous glutathione of NAC does not alter oxidized milieu in the endoplasmic reticulum. NAC

causes anti-apoptotic molecule Bcl-2 to significantly reduce apoptosis induced by pro-necrotic concentrations of certain cytotoxic drugs, including cisplatin.<sup>[14-17]</sup>

#### **Antiviral activities**

##### ***Influenza A***

An animal model of lethal influenza confirmed the effectiveness of combination therapy by demonstrating the effect of NAC in only 20% of cases due to its suboptimal dose and a survival increase of 60% with oseltamivir as an antiviral medicine and 100% with a combination of NAC and oseltamivir.<sup>[44]</sup>

Evaluating virus replication and virus-induced pro-inflammatory responses in H5N1-infected A549 lung epithelial cells found 5–15 mM NAC to reduce H5N1-induced cytopathogenic effects, virus-induced apoptosis, 24-h postinfection viral yield, pro-inflammatory molecules produced, i.e., CXCL8, CXCL10, CCL5, and interleukin-6, and monocyte migration towards the supernatant of the cells. The antiviral and anti-inflammatory mechanisms of NAC inhibited the activation of oxidant sensitive pathways, including transcription factors NF- $\kappa$ B and p38 mitogen-activated protein kinase. The effects of the pharmacological inhibitors of NF- $\kappa$ B (BAY 11-7085) and p38 (SB203580) resembled those of NAC on H5N1-infected cells. A combination of SB203580 and BAY 11-7085 raised inhibitory effects on virus replication and production of pro-inflammatory molecules in monotherapies. NAC inhibits H5N1 replication and H5N1-induced production of pro-inflammatory molecules.<sup>[45]</sup> NAC was found unable to alter the course of a fatal influenza pneumonia caused by inoculated murinized swine H1N1 influenza viruses. The inhibitory effects of NAC on swine virus reported *in vitro* were significantly lower than on other strains. NAC is not considered a universal treatment for influenza pneumonia given its strain-dependent effects on influenza viruses.<sup>[46]</sup> Although NAC was found to limit lung inflammation, viral growth and the virus-caused damage *in-vitro*, its antiviral activity significantly depended on the influenza A strain. These yet-unclear inter-strain variations can be related to the activation level of NF- $\kappa$ B required for the virus to achieve its infectious cycle.<sup>[47]</sup>

##### ***Epstein–Barr virus***

Given that NAC slows down the progression of pathology by reducing leukocyte recruitment to sites of inflammation, it can alleviate chronic inflammatory pathologies, including postviral diseases.<sup>[48]</sup>

##### ***HIV***

Given the reduction in intracellular glutathione levels of circulating T cells in HIV-infected patients, glutathione-replenishing drugs, including NAC can help

treat HIV. The difference between NAC and many other antiviral drugs lies in its ability to inhibit the host-mediated stimulation of viral replication in normal immune responses, which extends latency. Inhibiting inflammatory cytokines as mediators of cachexia by NAC supports its effectiveness in alleviating the deleterious effects of late-stage AIDS.<sup>[49,50]</sup>

HIV-seropositive patients with CD4 lymphocyte cell counts of over  $200 \times 10^6$  randomly received 800 mg of NAC or placebo for 4 months in a double-blind placebo-controlled trial. Low cysteine plasma levels, high free radical activity in neutrophils in the presence of autologous plasma measured with the nitroblue tetrazolium test, and increased tumor necrosis factor (TNF)-alpha levels were observed in the HIV patients before the treatment. Cysteine plasma increased to normal levels and TNF-alpha levels and the drop rate of CD4 + lymphocyte counts decreased in the NAC group compared to in the placebo group after the treatment. NAC did not affect the radical production by neutrophils, although it decreased the decline in CD4+ cells.<sup>[51]</sup>

### *Hepatitis virus*

An RCT recruited 13 females and 28 males hospitalized with acute viral hepatitis (AVH) and administered placebo capsules in controls and 200 mg of oral NAC three times daily in the experimental group to determine the efficacy of NAC, which was found ineffective in the time necessary for ALT normalization, total bilirubin, and length of stay. Despite its innocuous effects on AVH patients, NAC was not recommended for treating icteric AVH.<sup>[52]</sup> These findings can be explained by the low dose of oral NAC administered.

### *Preventive and therapeutic roles in pulmonary disorders Idiopathic pulmonary fibrosis*

Well-designed studies found insignificant differences in complications and mortality between two groups and NAC to reduce disease progression based on PaO<sub>2</sub> and improve pulmonary dysfunction based on forced-vital-capacity (FVC) and diffusion capacity of lung for carbon monoxide (DLCO) compared to in controls, which confirmed the efficacy, tolerability and safety of the treatment. Furthermore, subgroup analysis found combination therapy for IPF with NAC more effective than NAC monotherapy and oral NAC safer than inhalation. This review and meta-analysis provided valuable evidence that can be applied to clinically treating IPC with NAC.<sup>[53-62]</sup>

### *Chronic obstructive pulmonary disease*

NAC has been frequently found with anti-oxidative, anti-inflammatory, and positive mucolytic effects on COPD. Given the controversial findings on NAC effects on COPD outcomes, including exacerbation and changes in lung function, a systematic review and meta-analysis

found NAC ineffective in exacerbation, forced expiratory volume in 1 s, FVC, and inspiratory capacity and long-term administration of NAC effective in decreasing the COPD exacerbation risk.<sup>[63-71]</sup>

NAC was found to moderately and significantly affect aspergillosis and bacterial pulmonary infections, respectively.<sup>[72,73]</sup>

### *Pneumonia*

Ventilator-associated pneumonia (VAP) is characterized by mortality, morbidity, and prolonged stay in ICUs. As part of the pathogenic mechanism of community-acquired pneumonia (CAP), oxidative stress significantly relates to inflammation. Alleviating oxidative stress appears to decrease pulmonary damage. Research suggests no adverse NAC-associated events and significantly higher frequencies of complete recovery from VAP in NAC groups compared to in controls. NAC was found safe and effective in preventing and postponing VAP and improving its complete recovery in a selected high-risk ICU population. Investigating CAP patients showed insignificant differences in plasma superoxide dismutase activity and CT scores between controls and a group receiving NAC. Malondialdehyde and TNF- $\alpha$  decreased and total antioxidant capacity increased using NAC, which exerted no adverse effects on CAP patients. Moreover, NAC can reduce oxidative and inflammatory damage in pneumonia patients.<sup>[74,75]</sup>

### *Acute respiratory distress syndrome*

Compelling evidence suggests antioxidants and omega-3 fatty acids cause insignificant differences in all-cause mortality between adult groups with ARDS. The effect of immuno-nutrition with omega-3 fatty acids and antioxidants on ventilator days, ICU stay, and oxygenation at day 4 should be confirmed given the flimsy evidence available. Immuno-nutrition-associated adverse events should also be clarified given that confidence intervals might increase the risk of cardiac, gastrointestinal, and total adverse events. NAC reduces ICU stay despite its ineffectiveness in mortality and its limited effect on ARDS.<sup>[76-83]</sup>

### *Supportive roles in intensive care units*

Vitamin and high-dose trace element supplementation can improve outcomes in critically ill patients, especially those at increased risks of death. NAC can only be recommended for treating paracetamol poisoning, and its effect on other disorders is still being evaluated. High doses of NAC did not improve patient outcomes and increased the inflammation risk and serum creatinine.<sup>[84-87]</sup>

### *Sepsis*

Investigating septic patients showed insignificant differences in mortality between NAC groups and placebo

groups. NAC did not significantly affect lengths of stay and mechanical ventilation and incidence of organ failures. Neither the early application of NAC nor its application 24 h after developing symptoms, which related to cardiovascular instability, prevented oxidation inflammatory responses. NAC therefore appears ineffective in hemodynamic instability, including sepsis and septic shocks.<sup>[87-91]</sup>

### **Role in comorbidities and nonpulmonary end-organ damage or failure**

#### **Heart**

NAC is a nontoxic and safe antioxidant with mild adverse effects at high doses, including dizziness, hypotension, chest pain, bronchospasm, pruritus, rash, flushing, nausea, and vomiting. As an acetaminophen antidote, it appears to prevent cardiovascular disorders. Despite suggesting beneficial effects for NAC, literature contains controversies over its dose, time of administration, and duration of treatment in cardiovascular disorders. NAC has great potential for protecting diabetic heart at risks for myocardial infarction by inhibiting oxidative stress. The potential effects of NAC on ischemia and nonischemic-associated cardiac damage have attracted the attention of researchers; nevertheless, its administration during cardiac surgeries caused statistically-insignificant reductions in clinical outcomes. Large multi-center placebo-controlled RCTs are recommended for determining the effect of NAC on mortality in these settings.<sup>[92-94]</sup>

#### **Hypertension**

Research suggests ineffectiveness of NAC in blood pressure and surrogate markers for cardiovascular injury in nondiabetic patients with chronic kidney disease. In contrast, NAC combined with ACEIs was found to significantly decrease systolic and diastolic blood pressure, although ACEIs alone were ineffective in blood pressure. Systolic blood pressure decreased by 7 mmHg on an average.<sup>[95,96]</sup>

#### **Diabetes mellitus**

NAC can positively affect glutathione peroxidase in patients with Type II diabetes. NAC treatment with faster and more prolonged effects significantly improved cardiac function and decreased fibrosis. In cardiac fibroblasts, NAC blocked cardiac fibroblast proliferation and hyperglycemia-induced collagen synthesis. The present findings suggest NAC can protect diabetics against diabetic cardiomyopathy through inhibiting the ROS production and fibrosis, which should be investigated in future research.<sup>[97,98]</sup>

#### **Nephropathy**

The preventive effects of NAC resembled those of VC and NAC plus VC in patients with contrast-induced nephropathy (CIN) undergoing contrast administration.

In contrast to ascorbic acid (VC) and NAC plus VC, NAC significantly lowered serum creatinine levels. NAC plus statins plus IV saline appears the most effective in preventing CIN after coronary angiography (CAG). NAC plus IV saline can also protect from short-term all-cause mortality. None of these medications have, however, effectively reduced dialysis and major adverse cardiovascular events (MACE).<sup>[99]</sup>

#### **Liver failure**

##### **Nonparacetamol induced**

Despite the numerous positive findings, currently available scarce evidence is not compelling in terms of determining the role of NAC in nonparacetamol drug-induced liver injuries.<sup>[100]</sup>

##### **Paracetamol-induced**

NAC is a standard medication for liver injuries associated with acetaminophen. Despite reporting similar hepatotoxicity for IV and oral NAC in literature, comparisons should be drawn. Although disentangling the effects of dose and duration from those of route is difficult, the present findings suggest similar hepatotoxicity rates for IV and oral administration of NAC.<sup>[101]</sup>

#### **Other organs**

NAC is popular for its antitoxic properties in ototoxicity and acetaminophen poisoning. Evidence suggests the safety and otoprotective impact of NAC co-administered with aminoglycoside. The effect of concomitant NAC treatment on patients receiving aminoglycosides as part of multidrug-resistant tuberculosis treatment is recommended to be investigated.<sup>[102]</sup>

Given its oxidative regulatory and immune-regulatory effects and facilitation of oxygenation and circulation, a large body of literature was recently assigned to the efficacy of NAC in neurologic and psychiatric conditions, burns, and CO poisoning.<sup>[103-105]</sup>

There are documented with quality studies on efficacy of NAC in the treatment of viruses which target respiratory system and the related acute injuries such as ARDS (importantly by the drug's antioxidant and immunomodulatory roles), it is especially true about influenza (strains A and B) and respiratory syncytial virus (RSV) so that this drug has been highly recommended in the setting of influenza pandemic.<sup>[106-108]</sup>

Based on this review, there are many special probable therapeutic effects of NAC on COVID-19 and its consequences such as respiratory outcomes and other end-organ failures. We classified the probable effects of NAC in many categories such as oxidative-regulatory and



apoptotic-regulatory roles, antiviral activities, preventive and therapeutic roles in pulmonary disorders and better oxygenation, Supportive roles in ICUs and sepsis, positive role in comorbidities, and nonpulmonary end-organ damage or failure. NAC could be administered as a potential adjuvant therapy for COVID-19 considering patient status, contraindications and possible drug-related adverse events. Oral NAC may be recommended as a preventive or therapeutic agent for disease-related outcomes in stable nonseptic and nonintubated patients.

In the last update of this comprehensive review, we found the first rapid review on the evidence for effectiveness of NAC in treating COVID-19 that published on April 14 in CEBM of Oxford University, which resulted in us be so pleased that our hypothesis may be supported by other experts. In this review the authors had been focused on previous data of clinical trials justified use of NAC in COVID-19 like its use in influenza, bronchopulmonary disorders, and pneumonia<sup>[109]</sup> and also found other two studies focused on applicability of NAC usage in cytokine storm, dyspnea and ARDS related to COVID-19. This review is the most holistic study on the efficacy of NAC in various aspects of COVID-19.

### Limitations and recommendations

In the present study, there is no RCT that has used NAC in COVID-19 patients. In the latest search update of the article, three studies were found that their researchers agreed on the effect of NAC in COVID-19 patients.<sup>[109-111]</sup>

In addition, the field of COVID is of interest of the authors of this study and the author have been focused on other multi-potential drugs and specific manifestation of COVID and COVID in patients with specific disorders.<sup>[112-114]</sup>

Some clinical and therapeutic features of COVID-19 and its final sequels may become more clear and evident during time especially about nonrespiratory symptoms such as cutaneous signs and some of them could be targeted by NAC such as severe adverse cutaneous reactions that needs more focus in future studies.<sup>[26,27,113,114]</sup> In our medical field, dermatology, some cosmetic procedures and nonemergent surgeries could be postponed and some disorders may be managed by drugs that are effective for dermatologic diseases also be a potential preventive strategy for probable COVID in this pandemic area and NAC is among such drugs.<sup>[113,115,116]</sup>

### CONCLUSION

Given the special probable therapeutic effects of NAC on COVID-19 and its consequences, respiratory outcomes and other end-organ failures, NAC could be administered

as a potential adjuvant therapy for COVID-19 considering patient status, contraindications, and possible drug-related adverse events. Oral NAC is recommended as a preventive or therapeutic agent for disease-related outcomes in stable nonseptic and nonintubated patients. In this review, we classified the probable effects of NAC in many categories such as oxidative-regulatory and apoptotic-regulatory roles, antiviral activities, preventive and therapeutic roles in pulmonary disorders and better oxygenation, supportive roles in ICUs and sepsis, positive role in comorbidities and nonpulmonary end-organ damage or failure and even in primary COVID-associated cutaneous manifestations. IV NAC is recommended in case the efficacy is found valuable and significant. Analytical case-control studies and RCTs also finally systematically review of evidence are recommended for assessing NAC effects on COVID-19 outcomes.

### Acknowledgement

The authors would like to thank Rasoul Akram Hospital Clinical Research Development Center (RCRDC) for its technical and editorial assists.

### Financial support and sponsorship

Nil.

### Conflicts of interest

There are no conflicts of interest.

### REFERENCES

1. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment Coronavirus (COVID-19). Treasure Island, FL: StatPearls Publishing LLC; 2020.
2. McIntosh K, Hirsch MS, Bloom A. Coronavirus Disease 2019 (COVID-19). 2020, www.uptodate.com.
3. Cennimo DJ, Bronze MS. Coronavirus Disease 2019 (COVID-19) Treatment and Management. Medscape Updated; 2020.
4. Ashour HM, Elkhatab WF, Rahman MM, Elshabrawy HA. Insights into the recent 2019 novel coronavirus (SARS-CoV-2) in light of past human coronavirus outbreaks. *Pathogens* 2020;9:186.
5. Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G. Real estimates of mortality following COVID-19 infection. *Lancet Infect Dis* 2020;20:773.
6. Meo SA, Alhowikan AM, Al-Khlaiwi T, Meo IM, Halepoto DM, Iqbal M, *et al.* Novel coronavirus 2019-nCoV: Prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. *Eur Rev Med Pharmacol Sci* 2020;24:2012-9.
7. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. *Int J Antimicrob Agents* 2020;55:105924.
8. Gorbalenya A. The species severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. *Nat Microbiol* 2020;5:536-44.
9. Wu C, Chen X, Cai Y, Zhou X, Xu S, Huang H, *et al.* Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA Intern Med* 2020;180:934-43.

10. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, *et al.* Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. *Lancet* 2020;395:1054-62.
11. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? *Lancet Respir Med* 2020;8:e21.
12. Ershad M, Vearrier D. *N Acetylcysteine*. Treasure Island, FL: StatPearls Publishing; 2019.
13. Hołyńska-Iwan I, Wróblewski M, Olszewska-Słonina D, Tyrakowski T. The application of N-acetylcysteine in optimization of specific pharmacological therapies. *Pol Merkur Lekarski* 2017;43:140-4.
14. Demiralay R, Gürsan N, Erdem H. The effects of erdoesteine and N-acetylcysteine on apoptotic and antiapoptotic markers in pulmonary epithelial cells in sepsis. *Eurasian J Med* 2013;45:167-75.
15. Sun L, Gu L, Wang S, Yuan J, Yang H, Zhu J, *et al.* N-acetylcysteine protects against apoptosis through modulation of group I metabotropic glutamate receptor activity. *PLoS One* 2012;7:e32503.
16. Liu Y, Liu K, Wang N, Zhang H. N-acetylcysteine induces apoptosis via the mitochondria-dependent pathway but not via endoplasmic reticulum stress in H9c2 cells. *Mol Med Rep* 2017;16:6626-33.
17. Sancho-Martínez SM, Prieto-García L, Prieto M, Fuentes-Calvo I, López-Novoa JM, Morales AI, *et al.* N-acetylcysteine transforms necrosis into apoptosis and affords tailored protection from cisplatin cytotoxicity. *Toxicol Appl Pharmacol* 2018;349:83-93.
18. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, *et al.* Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. *Lancet* 2020;395:507-13.
19. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, *et al.* Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA* 2020;323:1061-9.
20. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, *et al.* Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395:497-506.
21. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, *et al.* Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med* 2020;382:1708-20.
22. Gorbalenya AE. Severe Acute Respiratory Syndrome-Related Coronavirus-The Species and its Viruses, a Statement of the Coronavirus Study Group. *BioRxiv*; 2020.
23. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, *et al.* Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med* 2020;8:420-2.
24. Wang T, Du Z, Zhu F, Cao Z, An Y, Gao Y, *et al.* Comorbidities and multi-organ injuries in the treatment of COVID-19. *Lancet* 2020;395:e52.
25. Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, *et al.* Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. *Lancet Respir Med* 2020;8:475-81.
26. Vélez A, Moreno JC. Toxic epidermal necrolysis treated with N-acetylcysteine. *J Am Acad Dermatol* 2002;46:469-70.
27. Hasan J, Ahmad J, Anam AM, Rabbani R. N-acetylcysteine in the effective management of TEN-associated severe skin lesions. *Adv Pharmacol Pharm* 2019;7:1-4.
28. Hamamsy ME, Bondok R, Shaheen S, Eladly GH. Safety and efficacy of adding intravenous N-acetylcysteine to parenteral L-alanyl-L-glutamine in hospitalized patients undergoing surgery of the colon: A randomized controlled trial. *Ann Saudi Med* 2019;39:251-7.
29. Millea PJ. N-acetylcysteine: Multiple clinical applications. *Am Fam Physician* 2009;80:265-9.
30. Rushworth GF, Megson IL. Existing and potential therapeutic uses for N-acetylcysteine: The need for conversion to intracellular glutathione for antioxidant benefits. *Pharmacol Ther* 2014;141:150-9.
31. Dhoubie IE, Jallouli M, Annabi A, Gharbi N, Elfazaa S, Lasram MM. A minireview on N-acetylcysteine: An old drug with new approaches. *Life Sci* 2016;151:359-63.
32. Mokhtari V, Afsharian P, Shahhoseini M, Kalantar SM, Moini A. A review on various uses of N-acetyl cysteine. *Cell J* 2017;19:11-7.
33. Pei Y, Liu H, Yang Y, Yang Y, Jiao Y, Tay FR, *et al.* Biological activities and potential oral applications of N-acetylcysteine: Progress and prospects. *Oxid Med Cell Longev* 2018;2018:2835787.
34. Thakker D, Raval A, Patel I, Walia R. N-acetylcysteine for polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled clinical trials. *Obstet Gynecol Int* 2015;2015:817849.
35. Oguz A, Uslukaya O, Alabalik U, Turkoglu A, Kapan M, Bozdag Z. Topical N-acetylcysteine improves wound healing comparable to dexpanthenol: An experimental study. *Int Surg* 2015;100:656-61.
36. Nakai K, Yoneda K, Murakami Y, Koura A, Maeda R, Tamai A, *et al.* Effects of topical N-acetylcysteine on skin hydration/transdermal water loss in healthy volunteers and atopic dermatitis patients. *Ann Dermatol* 2015;27:450-1.
37. Nakai K, Nishiura A, Ishikawa E, Moriue J, Moriue T, Kubota Y. Topical N-acetylcysteine can restore skin barrier function in healthy volunteers and atopic dermatitis patients. *J Dermatol Sci* 2017;86:e32.
38. Zargari O, Kianifar K. Clinical applications of N-acetylcysteine in dermatology. *J Dermatol Cosmet* 2010;1:201-6.
39. Baek J, Lee MG. Oxidative stress and antioxidant strategies in dermatology. *Redox Rep* 2016;21:164-9.
40. Adil M, Amin SS, Mohtashim M. N-acetylcysteine in dermatology. *Indian J Dermatol Venereol Leprol* 2018;84:652-9.
41. Šalamon Š, Kramar B, Marolt TP, Poljšak B, Milisav I. Medical and dietary uses of N-acetylcysteine. *Antioxidants (Basel)* 2019;8:111.
42. Rhodes K, Braakhuis A. Performance and side effects of supplementation with n-acetylcysteine: A systematic review and meta-analysis. *Sports Med* 2017;47:1619-36.
43. Janeczek M, Moy L, Riopelle A, Vetter O, Reserva J, Tung R, *et al.* The potential uses of N-acetylcysteine in dermatology: A review. *J Clin Aesthet Dermatol* 2019;12:20-6.
44. Garozzo A, Tempera G, Ungheri D, Timpanaro R, Castro A. N-acetylcysteine synergizes with oseltamivir in protecting mice from lethal influenza infection. *Int J Immunopathol Pharmacol* 2007;20:349-54.
45. Geiler J, Michaelis M, Naczek P, Leutz A, Langer K, Doerr HW, *et al.* N-acetyl-L-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus. *Biochem Pharmacol* 2010;79:413-20.
46. Garigliany MM, Desmecht DJ. N-acetylcysteine lacks universal inhibitory activity against influenza A viruses. *J Negat Results Biomed* 2011;10:5.
47. Casanova T, Garigliany M. N-acetylcysteine: An old drug with variable anti-influenza properties. *J Controvers Biomed Res* 2016;2:1-8.
48. Gao X, Lampraki EM, Al-Khalidi S, Qureshi MA, Desai R, Wilson JB. N-acetylcysteine (NAC) ameliorates Epstein-Barr virus latent membrane protein 1 induced chronic inflammation. *PLoS One* 2017;12:e0189167.
49. Roederer M, Ela SW, Staal FJ, Herzenberg LA, Herzenberg LA. N-acetylcysteine: A new approach to anti-HIV therapy. *AIDS Res Hum Retroviruses* 1992;8:209-17.
50. De Rosa S, Zaretsky M, Dubs J, Roederer M, Anderson M, Green A,

- et al.* N-acetylcysteine replenishes glutathione in HIV infection. *Eur J Clin Invest* 2000;30:915-29.
51. Akerlund B, Jarstrand C, Lindeke B, Sönnberg A, Akerblad AC, Rasool O. Effect of N-acetylcysteine (NAC) treatment on HIV-1 infection: A double-blind placebo-controlled trial. *Eur J Clin Pharmacol* 1996;50:457-61.
  52. Gunduz H, Karabay O, Tamer A, Ozaras R, Mert A, Tabak OF. N-acetyl cysteine therapy in acute viral hepatitis. *World J Gastroenterol* 2003;9:2698-700.
  53. Marchioni A, Tonelli R, Ball L, Fantini R, Castaniere I, Cerri S, et al. Acute exacerbation of idiopathic pulmonary fibrosis: Lessons learned from acute respiratory distress syndrome? *Crit Care* 2018;22:80.
  54. Qiu M, Chen Y, Ye Q. Risk factors for acute exacerbation of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. *Clin Respir J* 2018;12:1084-92.
  55. Canestaro WJ, Forrester SH, Raghu G, Ho L, Devine BE. Drug treatment of idiopathic pulmonary fibrosis: Systematic review and network meta-analysis. *Chest* 2016;149:756-66.
  56. Cu A, Ye Q, Sarria R, Nakamura S, Guzman J, Costabel U. N-acetylcysteine inhibits TNF-alpha, sTNFR, and TGF-beta1 release by alveolar macrophages in idiopathic pulmonary fibrosis *in vitro*. *Sarcoidosis Vasc Diffuse Lung Dis* 2009;26:147-54.
  57. Kandhare AD, Mukherjee A, Ghosh P, Bodhankar SL. Efficacy of antioxidant in idiopathic pulmonary fibrosis: A systematic review and meta-analysis. *EXCLI J* 2016;15:636-51.
  58. Rogliani P, Calzetta L, Cavalli F, Matera MG, Cazzola M. Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. *Pulm Pharmacol Ther* 2016;40:95-103.
  59. Sun T, Liu J, Zhao De W. Efficacy of N-acetylcysteine in idiopathic pulmonary fibrosis: A systematic review and meta-analysis. *Medicine (Baltimore)* 2016;95:e3629.
  60. Fleetwood K, McCool R, Glanville J, Edwards SC, Gsteiger S, Daigl M, et al. Systematic review and network meta-analysis of idiopathic pulmonary fibrosis treatments. *J Manag Care Spec Pharm* 2017;23:55-16.
  61. Guo J, Li B, Wu W, Wang Z, Wang F, Guo T. Chinese herbal medicines compared with N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review of randomized controlled trials. *Evid Based Complement Altern Med* 2019;2019:5170638.
  62. Feng F, Zhang J, Wang Z, Wu Q, Zhou X. Efficacy and safety of N-acetylcysteine therapy for idiopathic pulmonary fibrosis: An updated systematic review and meta-analysis. *Exp Ther Med* 2019;18:802-16.
  63. Sadowska AM. N-Acetylcysteine mucolysis in the management of chronic obstructive pulmonary disease. *Ther Adv Respir Dis* 2012;6:127-35.
  64. Santus P, Corsico A, Solidoro P, Braido F, Di Marco F, Scichilone N. Oxidative stress and respiratory system: Pharmacological and clinical reappraisal of N-acetylcysteine. *COPD* 2014;11:705-17.
  65. Grandjean EM, Berthet P, Ruffmann R, Leuenberger P. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: A meta-analysis of published double-blind, placebo-controlled clinical trials. *Clin Ther* 2000;22:209-2.
  66. Stey C, Steurer J, Bachmann S, Medici TC, Tramèr MR. The effect of oral N-acetylcysteine in chronic bronchitis: A quantitative systematic review. *Eur Respir J* 2000;16:253-62.
  67. Tse HN, Tseng CZ. Update on the pathological processes, molecular biology, and clinical utility of N-acetylcysteine in chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis* 2014;9:825-36.
  68. Matera MG, Calzetta L, Cazzola M. Oxidation pathway and exacerbations in COPD: The role of NAC. *Expert Rev Respir Med* 2016;10:89-97.
  69. Shen Y, Cai W, Lei S, Zhang Z. Effect of high/low dose N-acetylcysteine on chronic obstructive pulmonary disease: A systematic review and meta-analysis. *COPD* 2014;11:351-8.
  70. Fowdar K, Chen H, He Z, Zhang J, Zhong X, Zhang J, et al. The effect of N-acetylcysteine on exacerbations of chronic obstructive pulmonary disease: A meta-analysis and systematic review. *Heart Lung* 2017;46:120-8.
  71. Calzetta L, Matera MG, Rogliani P, Cazzola M. Multifaceted activity of N-acetyl-L-cysteine in chronic obstructive pulmonary disease. *Expert Rev Respir Med* 2018;12:693-708.
  72. Jeeraumponwat T. N-acetylcysteine and mortality in hospitalized pulmonary tuberculosis infection. *Eur Respir Soc* 2019;54:PA2958.
  73. Otu A, Langridge P, Denning DW. Nebulised N-acetylcysteine for unresponsive bronchial obstruction in allergic bronchopulmonary aspergillosis: A case series and review of the literature. *J Fungi (Basel)* 2018;4:117.
  74. Sharafkhan M, Abdolrazaghnejad A, Zarinfar N, Mohammadbeigi A, Massoudifar A, Abaszadeh S. Safety and efficacy of N-acetyl-cysteine for prophylaxis of ventilator-associated pneumonia: A randomized, double blind, placebo-controlled clinical trial. *Med Gas Res* 2018;8:19-23.
  75. Zhang Q, Ju Y, Ma Y, Wang T. N-acetylcysteine improves oxidative stress and inflammatory response in patients with community acquired pneumonia: A randomized controlled trial. *Medicine (Baltimore)* 2018;97:e13087.
  76. Soltan-Sharifi MS, Mojtahedzadeh M, Najafi A, Reza Khajavi M, Reza Rouini M, Moradi M, et al. Improvement by N-acetylcysteine of acute respiratory distress syndrome through increasing intracellular glutathione, and extracellular thiol molecules and anti-oxidant power: Evidence for underlying toxicological mechanisms. *Hum Exp Toxicol* 2007;26:697-703.
  77. Komiya K, Akaba T, Kozaki Y, Kadota JI, Rubin BK. A systematic review of diagnostic methods to differentiate acute lung injury/acute respiratory distress syndrome from cardiogenic pulmonary edema. *Crit Care* 2017;21:228.
  78. Zhang Y, Ding S, Li C, Wang Y, Chen Z, Wang Z. Effects of N-acetylcysteine treatment in acute respiratory distress syndrome: A meta-analysis. *Exp Ther Med* 2017;14:2863-8.
  79. Fan E, Brodie D, Slutsky AS. Acute respiratory distress syndrome: Advances in diagnosis and treatment. *JAMA* 2018;319:698-710.
  80. Nanchal RS, Truitt JD. Recent advances in understanding and treating acute respiratory distress syndrome. *F1000Res* 2018;7:F1000 Faculty Rev-1322.
  81. Yin J, Bai CX. Pharmacotherapy for adult patients with acute respiratory distress syndrome. *Chin Med J (Engl)* 2018;131:1138-41.
  82. Lu X, Ma Y, He J, Li Y, Zhu H, Yu X. N-acetylcysteine for adults with acute respiratory distress syndrome: A meta-analysis of randomized controlled trials. *Hong Kong J Emerg Med* 2019;26:1.
  83. Dushianthan A, Cusack R, Burgess VA, Grocott MP, Calder P. Immunonutrition for adults with ARDS: Results from a cochrane systematic review and meta-analysis. *Respir Care* 2020;65:99-110.
  84. Atkinson M. The use of N-acetylcysteine in intensive care. *Crit Care Resusc* 2002;4:21-7.
  85. Jelic S, Cunningham JA, Factor P. Clinical review: Airway hygiene in the intensive care unit. *Crit Care* 2008;12:209.
  86. Manzanares W, Dhaliwal R, Jiang X, Murch L, Heyland DK. Antioxidant micronutrients in the critically ill: A systematic review and meta-analysis. *Crit Care* 2012;16:R66.
  87. Najafi A, Mojtahedzadeh M, Ahmadi KH, Abdollahi M, Mousavi M, Chelkeba L, et al. The immunological benefit of higher dose N-acetyl cysteine following mechanical ventilation in critically ill patients. *Daru* 2014;22:57.



88. Spapen H. N-acetylcysteine in clinical sepsis: A difficult marriage. *Crit Care* 2004;8:229-30.
89. Visvanathan V. N-acetylcysteine for sepsis and systemic inflammatory response in adults. *Crit Care Nurse* 2013;33:76-7.
90. Chertoff J. N-acetylcysteine's role in sepsis and potential benefit in patients with microcirculatory derangements. *J Intensive Care Med* 2018;33:87-96.
91. Szakmany T, Hauser B, Radermacher P. N-acetylcysteine for sepsis and systemic inflammatory response in adults. *Cochrane Database Syst Rev* 2012;2012:CD006616.
92. Dlodla PV, Dias SC, Obonye N, Johnson R, Louw J, Nkambule BB. A systematic review on the protective effect of N-acetyl cysteine against diabetes-associated cardiovascular complications. *Am J Cardiovasc Drugs* 2018;18:283-98.
93. Dlodla PV, Mazibuko-Mbeje SE, Nyambuya TM, Mxinwa V, Tiano L, Marcheggiani F, *et al.* The beneficial effects of N-acetyl cysteine (NAC) against obesity associated complications: A systematic review of pre-clinical studies. *Pharmacol Res* 2019;146:104332.
94. Pereira JE, El Dib R, Braz LG, Escudero J, Hayes J, Johnston BC. N-acetylcysteine use among patients undergoing cardiac surgery: A systematic review and meta-analysis of randomized trials. *PLoS One* 2019;14:e0213862.
95. Renke M, Tylicki L, Rutkowski P, Larczynski W, Neuwelt A, Aleksandrowicz E, *et al.* The effect of N-acetylcysteine on blood pressure and markers of cardiovascular risk in non-diabetic patients with chronic kidney disease: A placebo-controlled, randomized, cross-over study. *Med Sci Monit* 2010;16:PI13-8.
96. Khaledifar A, Mobasheri M, Kheiri S, Zamani Z. Comparison of N-acetylcysteine and angiotensin converting enzyme inhibitors in blood pressure regulation in hypertensive patients. *ARYA Atheroscler* 2015;11:5-13.
97. Ozkilic AC, Cengiz M, Ozaydin A, Cobanoglu A, Kanigur G. The role of N-acetylcysteine treatment on anti-oxidative status in patients with Type II diabetes mellitus. *J Basic Clin Physiol Pharmacol* 2006;17:245-54.
98. Liu C, Lu XZ, Shen MZ, Xing CY, Ma J, Duan YY, *et al.* N-acetyl cysteine improves the diabetic cardiac function: Possible role of fibrosis inhibition. *BMC Cardiovasc Disord* 2015;15:84.
99. Ma WQ, Zhao Y, Wang Y, Han XQ, Zhu Y, Liu NF. Comparative efficacy of pharmacological interventions for contrast-induced nephropathy prevention after coronary angiography: A network meta-analysis from randomized trials. *Int Urol Nephrol* 2018;50:1085-95.
100. Chughlay MF, Kramer N, Spearman CW, Werfalli M, Cohen K. N-acetylcysteine for non-paracetamol drug-induced liver injury: A systematic review. *Br J Clin Pharmacol* 2016;81:1021-9.
101. Green JL, Heard KJ, Reynolds KM, Albert D. Oral and intravenous acetylcysteine for treatment of acetaminophen toxicity: A systematic review and meta-analysis. *West J Emerg Med* 2013;14:218-26.
102. Kranzer K, Elamin WF, Cox H, Seddon JA, Ford N, Drobniewski F. A systematic review and meta-analysis of the efficacy and safety of N-acetylcysteine in preventing aminoglycoside-induced ototoxicity: Implications for the treatment of multidrug-resistant TB. *Thorax* 2015;70:1070-7.
103. Bhatti J, Nascimento B, Akhtar U, Rhind SG, Tien H, Nathens A, *et al.* Systematic review of human and animal studies examining the efficacy and safety of N-acetylcysteine (NAC) and N-acetylcysteine amide (NACA) in traumatic brain injury: Impact on neurofunctional outcome and biomarkers of oxidative stress and inflammation. *Front Neurol* 2018;8:744.
104. Zheng W, Zhang QE, Cai DB, Yang XH, Qiu Y, Ungvari GS, *et al.* N-acetylcysteine for major mental disorders: A systematic review and meta-analysis of randomized controlled trials. *Acta Psychiatr Scand* 2018;137:391-400.
105. Elsharnouby NM, Eid HE, Elezz NF, Aboelatta YA. Heparin/ N-acetylcysteine: An adjuvant in the management of burn inhalation injury: A study of different doses. *J Crit Care* 2014;29:182.
106. Mata M, Morcillo E, Gimeno C, Cortijo J. N-acetyl-L-cysteine (NAC) inhibit mucin synthesis and pro-inflammatory mediators in alveolar Type II epithelial cells infected with influenza virus A and B and with respiratory syncytial virus (RSV). *Biochem Pharmacol* 2011;82:548-55.
107. Zhang RH, Li CH, Wang CL, Xu MJ, Xu T, Wei D, *et al.* N-acetyl-L-cystine (NAC) protects against H9N2 swine influenza virus-induced acute lung injury. *Int Immunopharmacol* 2014;22:1-8.
108. Hui DS, Lee N, Chan PK, Beigel JH. The role of adjuvant immunomodulatory agents for treatment of severe influenza. *Antiviral Res* 2018;150:202-16.
109. Van Hecke O, Lee J. N-Acetylcysteine: A Rapid Review of Evidence for Effectiveness in Treating COVID-19. *The Center of Evidence Based Medicine*; 2020.
110. Horowitz RI, Freeman PR, Bruzzese J. Efficacy of glutathione therapy in relieving dyspnea associated with covid-19 pneumonia: A report of 2 cases. *Respir Med Case Rep J* 2020;30:101063.
111. Assimakopoulos SF, Marangos M. N-acetyl-cysteine may prevent COVID-19-associated cytokine storm and acute respiratory distress syndrome. *Med Hypotheses* 2020;140:109778.
112. Seirafianpour F, Mozafarpoor S, Fattahi N, Sadeghzadeh-Bazargan A, Hanifiha M, Goodarzi A. Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy? *Dermatol Ther.* 2020 May 30:e13733. doi: 10.1111/dth.13733. Epub ahead of print. PMID: 32473070; PMCID: PMC7300917.
113. Seirafianpour F, Sodagar S, Pour Mohammad A, Panahi P, Mozafarpoor S, Almasi S, Goodarzi A. Cutaneous manifestations and considerations in COVID-19 pandemic: A systematic review. *Dermatol Ther.* 2020 Jul 8:e13986. doi: 10.1111/dth.13986. Epub ahead of print. PMID: 32639077; PMCID: PMC7362033.
114. Nobari NN, Goodarzi A. Patients with specific skin disorders who are affected by COVID-19: What do experiences say about management strategies? A systematic review. *Dermatol Ther* 2020;2020:e13867.
115. Ehsani A, Noormohammadpour P, Goodarzi A, Mirshams Shahshahani M, Hejazi SP, Hosseini E, *et al.* Comparison of long-pulsed alexandrite laser and topical tretinoin-ammonium lactate in axillary acanthosis nigricans: A case series of patients in a before-after trial. *Caspian J Intern Med* 2016;7:290-3.
116. Mohamadi MM, Goodarzi A, Aryannejad A, Fattahi N, Alizadeh-Khoei M, Miri S, *et al.* Geriatric challenges in the new coronavirus disease-19 (COVID-19) pandemic: A systematic review. *Med J Islam Repub Iran.* 2020;34:841-8.